Multiple dose bioequivalence study with josamycin propionate, a drug with highly variable kinetics, in healthy volunteers

International Journal of Clinical Pharmacology and Therapeutics

Volumn 34, Issue 5, 1996, Pages 202-207

  Van Hoogdalem, E J ^a   Terpstra, I J ^a   Krauwinkel, W J J ^a   Volkers Kamermans, N J ^a   Baven, A L M ^a   Verschoor, J S C ^a  

^a ASTELLAS PHARMA INC   (Japan)

Author keywords

Bioequivalence; High variability; Josamycin; Replicate design; Steady state

Indexed keywords

JOSAMYCIN; MACROLIDE;

AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BLOOD LEVEL; DRUG METABOLISM; FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION;

ADULT; ANTI-BACTERIAL AGENTS; BIOLOGICAL AVAILABILITY; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; FEMALE; HUMANS; JOSAMYCIN; MALE; REFERENCE VALUES; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES; SPECTROPHOTOMETRY, ULTRAVIOLET; TABLETS; THERAPEUTIC EQUIVALENCY;

EID: 0029993712     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Anonymous 1989 Investigation of bioavailability and bioequivalence. CPMP Guideline 111/54/89
2. Benet LZ 1992 Definitions and difficulties in acceptance criteria. BIO-International '92, May 20-22, Bad Homburg
3. Bergan T, Oydvin B 1972 Pharmacokinetics of josamycin - a new macrolide antibiotic. Pharmacology 7: 36-50
4. Blume HH, Scheidel B, Stewert M, Stenzhorn G 1992 Bioequivalence of highly variable drugs. I. Application of single-dose versus multiple-dose studies. BIO-International '92, May 20-22, Bad Homburg
5. Chiou WL 1978 Critical evaluation of the potential error in pharmacokinetic studies using the linear trapezoidal rule method for the calculation of the area under the plasma level-time curve. J Pharmacokin Biopharm 6: 539-546
6. Diletti E, Hauschke D, Steimjans VW 1992 Sample size determination: extended tables for the mutliplicative model and bioequivalence ranges of 0.9 to 1.11 and 0.7 to 1.43. Int J Clin Pharmacol Ther Toxicol 30: S59-S62
7. Gaffney M 1992 Variance components in comparative bioavailability studies. J Pharm Sci 81: 315-317
8. Liu J-P, Chow S-C 1992 Sample size determination for the two one-sided tests procedure in bioequivalence. J Pharmacokin Biopharm 20: 101-104
9. Midha KK, Hubbard JTW, Yeung PKF, Ormsby E, McKay G, Hawes EM, Korchinski ED, Gurnsey T, Rawson M, Schwede R 1992 Bioequivalence of highly variable drugs. I. Application of replicate design. BIO-International '92, May 20-22, Bad Homburg
10. Oosterhuis B, Jonkman JHG 1993 Pharmacokinetic studies in healthy volunteers in the context of in vitro/in vivo correlations. Eur J Drug Metab 18: 19-30
11. Osono T, Umezawa H 1985 Pharmacokinetics of macrolides, lincosamides and streptogramins, J. Antimicrob Chemother 16: 151-166
12. Privitera G, Bonino S, Del Mastro S 1985 Klinische Multicenterstudie mit Josamycinpropionate bei Kindern. Therapiewoche 35: 151-156
13. Reynolds JEF (ed) 1989 Martindale, the extra pharmacopoeia. 29th ed. The Pharmaceutical Press., London, 250
14. Schuirmann DJ 1987 A comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability. J Pharmacokin Biopharm 15: 657-680
15. Strausbaugh LJ, Bolton WK, Dilworth JA, Guerrant RL, Sande MA 1976 Comparative pharmacology of josamycin and erythromycin stearate. Antimicrob Agents Chemother 10: 450-456
16. Van Hoogdalem EJ, Oosterhuis B, de Bruin H, Hefting NR, Jonkman JHG 1992 Bioequivalentie en biologische beschikbaarherd. Pharm Weekbld 127: 1051-1053
17. Westlake WJ 1988 Bioavailability and bioequivalence of pharmaceutical formulations. In: Peace KE: Pharmaceutical statistics for drug development. Marcel Dekker, New York, 329-352
18. Wildfeuer A, Lemme J-D 1985 Zur Pharmacokinetik von Josamycin. Arzneim Forsch/Drug Res 35: 639-643